Company Filing History:
Years Active: 2013-2022
Title: Innovations by Harald Weninger: Pioneering Treatments for Neurodegenerative Disorders
Introduction: Harald Weninger, an accomplished inventor based in Vienna, Austria, has made significant contributions to the field of medical innovations. With a total of five patented inventions, his work primarily focuses on neurodegenerative disorders, particularly through the development of vaccines and therapeutic methods targeting synucleinopathies.
Latest Patents: Among Weninger’s latest patents are groundbreaking formulations for treating synucleinopathies. His inventions include a variety of peptides designed for therapeutic intervention, specifically mimotopes of alpha-synuclein. These patented methods detail the use of peptides such as (C)DQPVLPD (SEQ ID NO: 59), (C)DMPVLPD (SEQ ID NO: 60), and (C)DSPVLPD (SEQ ID NO: 61), among others. The comprehensive patents also cover peptides with various sequence IDs aimed at inducing immune responses to combat neurodegenerative diseases.
Career Highlights: Throughout his career, Weninger has associated with notable companies such as Affiris AG and AC Immune SA. His experiences in these innovative firms have enabled him to refine his research and contribute to significant advancements in the treatment of complex medical conditions. His continuous pursuit of knowledge and innovation positions him as a leader in his field.
Collaborations: Weninger has collaborated with esteemed professionals like Markus Mandler and Radmila Santic. These partnerships reflect a commitment to advancing medical science and finding effective solutions for debilitating neurodegenerative disorders.
Conclusion: Harald Weninger stands out as a visionary inventor dedicated to improving the lives of those affected by neurodegenerative diseases. His innovative patents and collaborations bear testament to his relentless pursuit of knowledge, and his contributions are sure to make a lasting impact on the field of medical therapies.